Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 193.22

+0.1%

1:17 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: B.D. who wrote (21694)	6/2/1998 12:57:00 PM
From: Webhead	Read Replies (3) of 32384

News! Well, RB I guess Bears know about going out on limbs! Volume going berzerk 581K 14 X 14 1/16 GAITHERSBURG, Md.,, June 2 (Reuters) - A Food and Drug Administration advisory panel recommended approval of Seragen Inc.'s new drug, Ontak, to treat a rare cancer called cutaneous T-cell lymphoma. The panel did not vote on U.S. Food and Drug Administration (FDA) approval, but said that the drug was safe and effective. Ontak was developed by Seragen and Eli Lilly and Co. . Ligand Pharmaceuticals will assume the rights to Ontak if a merger with Seragen is approved by the Securities and Exchange Commission. If the FDA follows the panel's advice, which it usually does, Ontak could be approved in six months.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next